Emerging ethical issues in pharmacogenomics: From research to clinical practice

American Journal of PharmacoGenomics

Volumn 2, Issue 4, 2002, Pages 273-281

  Freund, Carol L ^a   Wilfond, Benjamin S ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ORPHAN DRUG; TRASTUZUMAB;

BREAST CANCER; CLINICAL MEDICINE; CLINICAL TRIAL; DRUG EXPOSURE; DRUG SAFETY; DRUG SCREENING; DRUG USE; GENETIC COUNSELING; GENETIC PROCEDURES; GENETIC SELECTION; HUMAN; INFORMED CONSENT; MEDICAL CARE; MEDICAL ETHICS; PHARMACOGENOMICS; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; ANIMAL; ETHICS; GENETIC SCREENING; GENETICS AND REPRODUCTION; HUMAN EXPERIMENT; PHARMACOGENETICS; PROFESSIONAL PATIENT RELATIONSHIP;

GENETICS AND REPRODUCTION; PROFESSIONAL PATIENT RELATIONSHIP;

ANIMALS; GENETIC SCREENING; HUMANS; PHARMACOGENETICS; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 1842846685     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200202040-00007     Document Type: Review

References (61)

1. The Genome International Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921
2. Sander C. Genomic medicine and the future of health care. Science 2000; 287 (5460): 1977-8
3. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355 (9212): 1358-61
4. Beaudet AL. 1998 ASHG presidential address. Making genomic medicine a reality. Am J Hum Genet 1999; 64 (1): 1-13
5. Collins FS. Shattuck lecture: Medical and societal consequences of the Human Genome Project. N Engl J Med 1999; 341 (1): 28-37
6. Weber WW. Pharmacogenetics. New York: Oxford University Press, 1997
7. Grant DM, Hughes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutat Res 1997; 376 (1-2): 61-70
8. Polymeropoulos M. Application of genetics and genomics in drug development. Drug Dev Res 2000; 49: 43-5
9. Regalado A. Inventing the pharmacogenomics business. Am J Health Syst Pharm 1999; 56 (1): 40-50
10. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286 (5439): 487-91
11. Sadée W. Pharmacogenomics. BMJ 1999; 319 (7220): 1286-9
12. Bailey DS, Bondar A, Furness LM. Pharmacogenomics: It's not just pharmacogenetics. Curr Opin Biotechnol 1998; 9 (6): 595-601
13. DiMasi JA. Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 2001; 69 (5): 297-307
14. McCarty NA, Standaert TA, Teresi M, et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol 2002; 33 (2): 90-8
15. Roomans GM. Pharmacological treatment of the ion transport defect in cystic fibrosis. Expert Opin Investig Drugs 2001; 10 (1): 1-19
16. Clayton EW, Steinberg KK, Khoury MJ, et al. Informed consent for genetic research on stored tissue samples. JAMA 1995; 274 (22): 1786-92
17. Grizzle W, Grody WW, Noll WW, et al. Recommended policies for uses of human tissue in research, education, and quality control. Ad Hoc Committee on Stored Tissue. College of American Pathologists. Arch Pathol Lab Med 1999; 123 (4): 296-300
18. National Bioethics Advisory Commission. Research Involving Human Biological Materials: Ethical Issues and Policy Guidance. Rockville (MD): National Bioethics Advisory Commission, 1999
19. Persidis A. Pharmacogenomics and diagnostics. Nat Biotechnol 1998; 16 (8): 791-2
20. Bodenheimer T. Uneasy alliance: Clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342 (20): 1539-44
21. Housman D, Ledley FD. Why pharmacogenomics? Why now? Nat Biotechnol 1998; 16 (6): 492-3
22. Murphy MP, Beaman ME, Clark LS, et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. Pharmacogenetics 2000; 10 (7): 583-90
23. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001; 2 (3): 228-31
24. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000; 283 (20): 2701-11
25. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000; 11 (6): 647-63
26. Schneider LS, Olin JT, Lyness SA, et al. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997; 45 (8): 923-8
27. Sherman LA, Temple R, Merkatz RB. Women in clinical trials: An FDA perspective. Science 1995; 269 (5225): 793-5
28. Kauffman RE. Clinical trials in children: Problems and pitfalls. Paediatr Drugs 2000; 2 (6): 411-8
29. Haffner ME. Orphan drug product regulation: United States. Int J Clin Pharmacol Ther 2002; 40 (2): 84-8
30. Wendler D. When should "riskier" subjects be excluded from research participation? Kennedy Inst Ethics J 1998; 8 (3): 307-27
31. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287 (13): 1690-8
32. Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: Do recent market removals mean there is a problem? JAMA 1999; 281 (18): 1728-34
33. Fuller BP, Kahn MJ, Barr PA, et al. Privacy in genetics research. Science 1999; 285 (5432): 1359-61
34. Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies. Lessons from cystic fibrosis. JAMA 1993; 270: (24): 2948-54
35. Holtzman NA, Watson MS, editors. Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. Washington, DC: NIH-DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Research. Task Force on Genetic Testing, 1997: 180
36. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405 (6788): 857-65
37. Hayden MR, Kremer B. Huntington disease. In: Scriver CR, Sly WS, Childs B, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. 8th Ed. New York: McGraw-Hill, 2001: 5677-701
38. Couch FJ, Weber BL. Breast cancer. In: Scriver CR, Sly WS, Childs B, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. 8th Ed. New York: McGraw-Hill, 2001: 999-1031
39. Wilfond BS, Taussig LM. Cystic fibrosis: General overview. In: Tausig LM, Landau LI, editors. Pediatric Respiratory Medicine. Baltimore: Mosby, 1999: 982-90
40. Welsh MJ, Ramsay BW, Accurso F, et al. Cystic fibrosis. In: Scriver CR, Sly WS, Childs B, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. 8th Ed. New York: McGraw-Hill, 2001: 5121-88
41. Ventura SJ, Martin JA, Curtain SC, et al. Births: Final data for 1998. Natl Vital Stat Rep 2000; 48 (3): 1-2
42. McLeod HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14 (4): 567-72
43. Reported Tuberculosis in the United States 1999. Bethesda (MD): Centers for Disease Control and Prevention. 2000 Aug; Available from URL: www.lungusa.org/advocacy/107/PP107_TB.pdf [Accessed 2002 Oct 2]
44. Arinami T, Ishiguro H, Onaivi ES. Polymorphisms in genes involved in neurotransmission in relation to smoking. Eur J Pharmacol 2000; 410 (2-3): 215-26
45. Spitz MR, Shi H, Yang F, et al. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 1998; 90 (5): 358-63
46. Lerman C, Caporasi N, Main D, et al. Depression and self-medication with nicotine: The modifying influence of the dopamine D4 receptor gene. Health Psychol 1998; 17 (1): 56-62
47. Sabol SZ, nelson ML, Fisher C, et al. A genetic association for cigarette smoking behavior. Health Psychol 1999; 18 (1): 7-13
48. Centers for Disease Control. Cigarette smoking among adults: United States 1998. MMWR Morb Mortal Wkly Rep 2000; 49 (39): 881-4
49. Andrews LB, Fullerton JE, Holtzman F, et al., editors. Assessing Genetic Risks: Implications for Health and Social Policy. Washington, DC: National Academy Press, 1994: 338
50. McKinney EF, Walton RT, Yudkin P, et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 2000; 10 (6): 483-91
51. Schulte PA, Lomax GP, Ward EM, et al. Ethical issues in the use of genetic markers in occupational epidemiologic research. J Occup Environ Med 1999; 41 (8): 639-46
52. Nebert DW. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist? Clin Genet 1999; 56 (4): 247-58
53. Lowrance WW. The promise of human genetic databases. BMJ 2001; 322 (7293): 1009-10
54. ASHG/ACMG. Report Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995; 57: 1233-41
55. Clarke A. The genetic testing of children: Working Party of the Clinical Genetics Society (UK). J Med Genet 1994; 31 (10): 785-97
56. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta (2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162 (1): 75-80
57. Doukas DJ. Primary care and the human genome project: Into the breach. Arch Fam Med 1993; 2(11): 1179-83
58. Hofman KJ, Tambor ES, Chase GA, et al. Physicians' knowledge of genetics and genetic tests. Acad Med 1993; 68 (8): 625-32
59. Robertson JA. Consent and privacy in pharmacogenetic testing. Nat Genet 2001; 28 (3): 207-9
60. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344 (8935): 1453-7
61. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 72 (4): 646-51